These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 23926618)
1. A star rises, another fades. Neumann ME Nephrol News Issues; 2013 Jul; 27(8):8. PubMed ID: 23926618 [No Abstract] [Full Text] [Related]
2. Rebates for anti-anemia drugs draw response from FDA, CMS. Sipkoff M Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732 [No Abstract] [Full Text] [Related]
3. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO? Besarab A; McCrea JB ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674 [No Abstract] [Full Text] [Related]
4. Darbepoetin alpha is highly cost-effective compared with epoetin alpha in the treatment of renal anemia: a brief report from a hemodialysis clinic in Japan. Nakagawa T Ther Apher Dial; 2008 Dec; 12(6):531-2. PubMed ID: 19140854 [No Abstract] [Full Text] [Related]
5. Finding a rational approach to ESA therapy--for payers and patients. Messana A Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481 [No Abstract] [Full Text] [Related]
13. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Duh MS; Mody SH; Scott McKenzie R; Lefebvre P; Gosselin A; Tak Piech C Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316 [TBL] [Abstract][Full Text] [Related]
14. [Cost minimisation analysis for darbepoetin alpha vs. epoetin alpha in chronic kidney disease patients on haemodialysis]. Cuesta Grueso C; Poveda Andrés JL; Garcia Pellicer J; Romá Sánchez E Farm Hosp; 2010; 34(2):68-75. PubMed ID: 20206567 [TBL] [Abstract][Full Text] [Related]
16. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan. Wish JB Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798 [TBL] [Abstract][Full Text] [Related]
17. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. Abraham I; Han L; Sun D; MacDonald K; Aapro M Future Oncol; 2014; 10(9):1599-609. PubMed ID: 25145430 [TBL] [Abstract][Full Text] [Related]
18. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia. Yang MC Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351 [No Abstract] [Full Text] [Related]
19. Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients. Ofsthun NJ; Lazarus JM Blood Purif; 2007; 25(1):31-5. PubMed ID: 17170534 [TBL] [Abstract][Full Text] [Related]
20. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study. Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]